삼성제약 Stock: price and insider trades · South Korea
삼성제약: what insiders have been doing
Every trade that managers of 삼성제약 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. In the past year (1 November 2025 to 1 November 2026), 3 filings came from 2 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
With 3 filings in twelve months, the company is quieter than the median of 7 filings across the 2,655 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at no purchases and 5 sales.
There has been no open-market purchase by an insider of 삼성제약 for at least a year.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- 0KRXDART:20241224000501
- ShareKRXDART:20240712000309
- ShareKRXDART:20240507000406
- ShareKRXDART:20240507000409
- ●Executives0DART
- ShareKRXDART:20230426000650
- ShareKRXDART:20230426000571
- 0KRXDART:20230421000697
- ●Executives0DART
- ●Executives0DART
- 0KRXDART:20221202000546
- ●Executives0DART
- ●Executives0DART
- 0KRXDART:20211230000416
- 0KRXDART:20210910000413
- ●Executives0DART
21 of 21 declarations
About 삼성제약
Samsung Pharmaceutical is a South Korean company specializing in the health and pharmaceutical sector. It is listed on the KRX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
